The Universal Flu Vaccine Multi-Season Multi-Strain Vaccine C - - PowerPoint PPT Presentation

▶
the universal
SMART_READER_LITE
LIVE PREVIEW

The Universal Flu Vaccine Multi-Season Multi-Strain Vaccine C - - PowerPoint PPT Presentation

Aug 15, 2023 161 likes •406 views

The Universal Flu Vaccine Multi-Season Multi-Strain Vaccine C ORPORATE P RESENTATION Q4 2017 2 S AFE H ARBOR S TATEMENT This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction. All statements

slide-1
SLIDE 1

The Universal Flu Vaccine

Multi-Season Multi-Strain Vaccine

CORPORATE PRESENTATION Q4 2017

slide-2
SLIDE 2 This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction. All statements in this communication, other than those relating to historical facts, are "forward-looking statements" within the meaning of the United States Private Litigation Reform Act of 1995.You can identify forward-looking statements by terms including ‘‘anticipates,’’ ‘‘believes,’’ ‘‘could,’’ ‘‘estimates,’’ ‘‘expects,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘plans,’’ ‘‘potential,’’ ‘‘predicts,’’ ‘‘projects,’’ ‘‘should,’’ ‘‘will,’’ ‘‘would,’’ and similar expressions intended to identify forward-looking statements. These forward- looking statements relate to our business and financial performance and condition, as well as our plans, strategies, objectives and expectations for our business,
  • perations and financial performance and condition. However, these forward-looking statements are not guarantees of future performance and are subject to a number
  • f assumptions, involve known and unknown risks, many of which are beyond our control, uncertainties and other factors that may cause our actual results, performance
  • r achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important
factors that could cause actual results to differ materially from our expectations include, among others: the risk that drug development involves a lengthy and expensive process with uncertain outcome; BiondVax's ability to successfully develop and commercialize its pharmaceutical product; the length, progress and results of any clinical trials; the introduction of competing products; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals to commercialize BiondVax's products; the difficulty in evaluating business prospects; lack of sufficient funding to finance the clinical trials; termination of license agreement with Yeda which is the owner of certain patents, patent applications and other intellectual property, as a result of dispute that can arise with Yeda or the failure of BiondVax to comply with financial and other terms of the license; the difficulty of predicting actions of the U.S.A FDA; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; changes in the global pharmaceutical industry; changes in customers’ budgeting priorities; European Medicines Agency and other regulatory authority approvals; natural disasters; labor disputes; rising interest rates; general market, political
  • r economic conditions in the countries in which we operate; pension and health insurance liabilities; volatility or crises In the financial market; arbitration, litigation and
regulatory proceedings; and war or acts of terror; Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. Readers are urged to carefully review and consider the various disclosures made in the Company’s SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects. These forward-looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason. whether as a result of new information, future events or otherwise, except as required by law.

SAFE HARBOR STATEMENT

One • For All : The Universal Flu Vaccine

2

slide-3
SLIDE 3

BIONDVAX’S 2017 HIGHLIGHTS

1. http://www.biondvax.com/2017/06/biondvaxs-ceo-provides-first-half-2017-general-corporate-update/ 2. http://www.biondvax.com/2017/03/biondvax-approved-for-grant-from-israels-ministry-of-economy-and-industry-to-build-facility-for-commercial-scale-production-of-its-universal-flu-vaccine/ 3. http://www.biondvax.com/2017/06/european-investment-bank-eib-supports-late-stage-development-and-production-of-biondvaxs-universal-flu-vaccine-candidate-under-horizon-2020-initiative/ 4. http://www.biondvax.com/2017/07/biondvax-reports-positive-phase-2b-clinical-trial-results-for-its-universal-flu-vaccine/ 5. http://www.biondvax.com/2017/09/biondvax-announces-closing-of-10-million-public-offering-of-american-depositary-shares-and-exercise-of-over-allotment-option/

3

Israeli government support mid-size commercial facility2 – March 30

Ministry of Economy granted 20% of a NIS 20m budget towards construction

€20 million non-dilutive funding3 – June 19

The European Investment Bank (EIB) signed an agreement to support commercial scale production and Phase 3

BiondVax successfully meets Phase 2b clinical trial endpoints4 – July 20

M-001 showed statistically significant elevated T-cell immune responses, good safety profile and well-tolerated

$10 million secondary offering5 – September 18

Following the placement, BiondVax has 3 large strategic investors, each holding 5% to 20%

“…We now have the resources to launch our Phase 3 program towards commercialization.” 1

slide-4
SLIDE 4

Flu

infects up to 20%

  • f the

population each year … and kills

slide-5
SLIDE 5

The Flu Virus: Frequent and Unpredictable Mutations

A SEASONAL PROBLEM… A PANDEMIC THREAT

SEASONAL FLU

  • Per year: 23,000 deaths1 (21,000 elderly) &

200,000 hospitalizations2 in just the US

  • Worldwide annual death toll of 250,000-

500,0004; Flu & pneumonia are 8th leading cause

  • f death3 in the US
  • $87B economic burden5 in the US of which $56B

is in the elderly PANDEMIC FLU

  • When?… Where?... Which?… pandemic strain
  • Pandemic strain: a new to Humans
  • Past century: 4 major pandemics with over

100M deaths5

  • The 1918 Spanish Flu cost to global GDP6 was 4.8%
  • r over $3T in today’s dollars

“I rate the chances of a widespread epidemic in my lifetime at well over 50%” – Bill Gates

https://youtu.be/9AEMKudv5p0

5

1 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5933a1.htm#tab2; 2 http://www.cdc.gov/flu/about/qa/disease.htm; 3 http://www.cdc.gov/nchs/fastats/deaths.htm; 4 http://www.who.int/mediacentre/factsheets/fs211/en/ 5 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25 (2007) 5086–5096; 6 1918 Influenza: the Mother of All Pandemics, Volume 12, Number 1—January 2006, CDC; 7 World Bank 2014:Pandemic Risk
slide-6
SLIDE 6

CURRENT VACCINE FALLS SHORT: THE MISMATCH

1 Center for Disease Control: http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm 2 World Health Organization: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf

Seasonal Flu Vaccine Effectiveness (VE)

CDC data

1, flu seasons 2004-2017

Why current solutions fall short…

  • Past strains selection  Mismatch

phenomenon

  • Previous season’s vaccine will not necessarily

protect against next season’s flu strains

  • 4-6 month production lag

As low as

9% VE

in elderly2 Average 40% VE in general population

6

42% 48% 19% 52% 49% 47% 60% 56% 41% 37% 52% 21% 10% 2016-17 2015-16 2014-15 2013-14 2012-13 2011-12 2010-11 2009-10 2008-09 2007-08 2006-07 2005-06 2004-05
slide-7
SLIDE 7

THE ELDERLY – AT RISK AND IN NEED

  • ~90% of seasonal flu related death occurs in elderly
  • Seasonal vaccine effectiveness as low as 9% for elderly1
  • 86% of adults 65+ have chronic conditions2
  • Influenza worsens outcomes of chronic illness
  • Elderly flu cost in US estimated3 at $56B per year

(hospitalization, mortality, lost earnings)

1 World Health Organization: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf 2 https://www.ncoa.org/healthy-aging/flu-you/flu-facts/ 3 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25 (2007) 5086–5096 4 http://ije.oxfordjournals.org/content/35/2/352.short

NIH: “During the period from 1989 to 1997 the vaccination rate for elderly persons ≥65 years of age in the US increased from 30 to 67%. Despite this increase in coverage, mortality and hospitalization rates continued to increase rather than decline as would be expected...”

International Journal of Epidemiology4 (Vol. 35, Issue 2, P352-353)

7

slide-8
SLIDE 8

MEETING MILESTONES & CATALYSTS

2008

1st of two Phase 1/2 (IL)

May 2015 Nasdaq: BVXV 2010

1st of four Phase 2 (IL, EU)

Technology developed by Prof. Ruth Arnon Mid 90’s June 2007 TASE:BVXV BiondVax Operational 2005

EMA or EOP2M1 Phase 3 ready

2018

1 End of Phase 2 Meeting with the FDA or EMA prior to phase 3 Well known for the development of

Solid Science, Advanced Clinical Stage, Strong IP

FDA accepts IND

One • For All : The Universal Flu Vaccine

The Vaccine is Safe and Immunogenic

  • 698 young adult to elderly have participated in clinical trials
  • The vaccine was shown to be safe and immunogenic in all studies

2017

8

USA NIH Phase 2 USA CMO Phase 3 material Mid-size manufacturing plant construction June 2017 €20M EIB

Successful Phase 2b (EU)
slide-9
SLIDE 9

THINKING OUTSIDE THE BOX

BiondVax’s M-001 Existing vaccines

Universal: Broad coverage Strain specific Single formulation enabling year-round vaccination New vaccine every year Quick, robust year-round production (6-8 weeks) Long (4-6 month) production cycle Induces cellular (CMI) and enhances humoral (HAI priming effect) immune response to flu Limited vaccine effectiveness

Target Common Regions

Nine common regions (epitopes) of flu strains are connected to make one recombinant protein called M-001 produced in E.coli

HemAgglutinin (HA) NucleoProtein (NP) Matrix protein (M1)

The Influenza Virus

Universal Flu Vaccine

A common denominator for Seasonal & Pandemic strains

BiondVax’s Key Advantages

One • For All : The Universal Flu Vaccine

9

slide-10
SLIDE 10

M-001: ONE MULTI-SEASON & STRAIN FLU VACCINE

One • For All : The Universal Flu Vaccine

10

  • The human immune system has two arms:
  • Humoral: B-cells that produce antibodies.
  • Cellular (CMI): T-cells that produce cytokines with anti-viral activities.
  • Current flu vaccines mainly induce antibodies (HAI) against specific flu virus

strains (variable immunodominant regions of HA).

  • However, viruses are intracellular parasites, thus mostly are out of reach of our

immune system’s antibodies. However, T-cells target viruses within host cells.

  • M-001 was designed to induce T-cells that target common and conserved

regions of flu viruses and to produce anti-viral cytokines such as INF-gamma and IL-2. Indirectly, M-001 has a T-cell priming effect that enhances B-cell (HAI) responses to flu viruses.

  • Thus, M-001’s dual mode of action potentially can offer multi-season and

multi-strain protection.

slide-11
SLIDE 11

In the clinical trials we looked for the intrinsic CMI M-001 immunogenicity compared to baseline and its priming effect

SUCCESSFUL CLINICAL TRIALS

Results Status Total Participants Population (age) Year Trial Phase M-001 was well tolerated and a cellular (CMI) and humoral (priming effect) immune response was

  • bserved

Completed 63 Younger Adults (18-49) 2009 BVX-002 1/2 Completed 60 Older Adults (55-75) 2010 BVX-003 1/2 Completed 200 Younger Adults (18-49) 2011 BVX-004 2 Completed 120 Elderly (65+) 2012 BVX-005 2 Completed 36 Older Adults (50-65) 2015 BVX-006 2 Completed 219 EU Adults (18-60) 2015-16 BVX-007* 2b 698 Ongoing collaboration with NIH 180 USA Adults (18-45) 2016 BVX-008 2 In preparation 7,700 East EU Adults (50+) 2018 BVX-010 3

One • For All : The Universal Flu Vaccine

M-001: Safe and Immunogenic in Young Adults to Elderly

11

* BVX-007 was conducted in collaboration with the EU’s UNISEC consortium

  • No treatment-related severe adverse events
  • Adverse events were mild to moderate
  • All adverse events observed were transient
  • Both cellular and humoral immunity were induced
slide-12
SLIDE 12 0.05 0.1 0.15 0.2 0.25 0.3 A/Brisbane/10/07 H3N2 A/California/7/09 H1N1 A/Perth/16/09 H3N2 B/Brisbane/60/08 Flumist % Positive of all cells Baseline Day 42 (after M-001 x2)

* *

0.05 0.1 0.15 0.2 0.25 0.3 A/Brisbane/10/07 H3N2 A/California/7/09 H1N1 A/Perth/16/09 H3N2 B/Brisbane/60/08 Flumist 2011 % positive cells (Mean + SE) M-001 twice Day 0 M-001 twice Day 42 * * * * **

M-001: DESIGNED FOR CELL MEDIATED IMMUNITY

* P<0.05 **P<0.07

12

* * *

1 Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the elderly population. Vaccine 32 (2014) 5816–5823

Direct Evidence: CD8, CD4 T-cell Activated Cells Produce TH1 Cytokines (IFN-gamma, IL-2 & TNF-alpha)

BVX0051: CD8 & IFN-gamma in Elderly BVX0051: CD4 & IFN-gamma in Elderly

“Multiple-Cytokine- Producing Antiviral CD4 T Cells Are Functionally Superior to Single- Cytokine-Producing Cells”

S Kannanganat et al, J VIROL, 2007, 81(16)8468–76 211 134 1347 663 347
  • 200
200 400 600 800 1000 1200 1400 high any low any high 2/3 low 2/3 high combi low combi

% over placebo * * * *

Single Double Triple M-001: 1mg 0.5mg 1mg 0.5mg 1mg 0.5mg

UNISEC (EU): 13 fold increase in responders expressing 2 cytokines (18-60 Y)

678 380 530 474 38
  • 23
  • 200
200 400 600 800 1000 high INF low INF highIL2 low il2 high tnfa low tnfa

% over placebo

M-001: 1mg 0.5mg 1mg 0.5mg 1mg 0.5mg IFN-gamma IL-2 TNF-alpha

UNISEC (EU): statistically significant anti viral cytokines

* P<0.05 * P<0.05 * P<0.05
slide-13
SLIDE 13

H1N1 pandemic swine flu

M-001: DESIGNED FOR CELL MEDIATED IMMUNITY

13

10 20 30 40 50 60 70 TIV 2011/12 M-001 & TIV 2011/12 % Seroprotection (HAI)

*

“M-001 can provide broadened enhanced immunity extending even to influenza strains destined to circulate in future years.” – Vaccine 2

In 2011 we administered M-001 to seniors 65+ (BVX005) 4 years later, 5 times more seniors were seroprotected from a new epidemic strain (A/Swiss) that didn’t exist in 2011!

  • 1. Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the
elderly population. Vaccine 32 (2014) 5816–5823
  • 2. Lowell GH et al. Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune
responses against 2014/15 epidemic strain. Vaccine (2017)

Indirect Evidence: Extending T-Cell Priming Effect for Enhanced HAI Responses to Current Flu Vaccines

BVX0051: 2012, age 65+ YO BVX003: 2009, age 55-75 YO

10 20 30 40 50 60 70 A/California/7/09 A/Perth/16/09 B/Brisbane/60/08 % Seroconversion TIV Twice M-001 + TIV

*

10 20 30 40 50 60 70 80 A/Brisbane/59/07 A/Brisbane/10/07 B/Brisbane/60/08 % seroconversion TIV Twice M-001 + TIV

* P<0.05

slide-14
SLIDE 14

PIVOTAL CLINICAL EFFICACY PHASE 3 DESIGN

14

  • Sample size: ~7,700 participants with flexible enrollment (TBD)
  • Population: 50+ years old; stratification to <65> years old (TBD)
  • Endpoint: Clinical efficacy by reduction of illness rate and severity
  • Phase 3 ready: First participant group enrollment expected autumn 2018

Proposed Trial Design Season 1 Season 2 Season 3 (optional) Day 1 Day 21 Day 180 Follow up Follow up Experimental 1mg M-001 1mg M-001 Safety, PCR and culture on any ILI (flu season) PCR and culture

  • n any ILI

(flu season) PCR and culture on any ILI (flu season) Control Placebo Placebo

Opportunity: Financing and Phase 2 Trial Results Leads to Clinical Efficacy Phase 3

One • For All : The Universal Flu Vaccine

Study title: A multicenter, randomized, double-blind, placebo-controlled pivotal phase 3 trial to assess the safety and clinical efficacy of a M-001 influenza vaccine administered intramuscularly twice in old adults and elderly (≥50 YO)

slide-15
SLIDE 15

PRODUCTS NEED PRODUCTION

15

  • From pilot GMP to mid-size GMP manufacturing facility (Israel)*
  • Funding: EIB, BiondVax, and Israel’s Ministry of Economy & Industry
  • Capacity: up to 20 million single-doses or 40 million doses (bulk) per year
  • Year-round Production & Stockpile per market demand

Goal: Fully Integrated Pharma Operating Under International GMP Standards

* BiondVax is collaborating with a US-based contract manufacturer

  • rganization (CMO) for upscaling and optimization
slide-16
SLIDE 16

BIONDVAX: FIRST-IN-CLASS, BEST-IN-CLASS

One • For All : The Universal Flu Vaccine

16

Player Technology Strength

Phase

Progress Reported

Pre- clinical I II III

Synthetic protein B- & T-cell peptides (HA, M1, NP)
  • Broad coverage
  • Large # of human clinical
trials
  • Young to elderly
Q3-2017: Statistically significant European Ph2b trial UNISEC consortium. NIAID/NIH sponsored
  • ngoing collaboration Phase 2 in USA.
Preparing for Phase 3 in the EU. 4 T-cell peptides adjuvanted formulation
  • Small challenge trial
Participated in UNISEC consortium. 2016: Created Imutex with hVIVO; Phase 2b challenge study Adenovirus vector expressing Influenza A conserved NP and M1 proteins
  • T-cell boost when
administered with TIV Preparing for Ph2 in 2000 participants. Oxford University spinoff, raised £10m in 2016. Broad seasonal and pandemic candidate. T-cell booster
  • Intranasal, replication
deficient adenovirus Formerly ITS then Vaxin. Phase 2 expected start Q3-2017. Merged PharmaAthene, listed on NASDAQ DNA constructs encoding HA proteins
  • Versatile technology of mix
and match Q3-2012 Phase 1 Single replication virus, M2SR; Broadening immunogenicity to flu sub type H3N2
  • Immunogenic in mice
Q3-2016 Phase I, H3N2 Raised $27m, including $5.5m Aug 2017 Stem-only immunogens based on rational design
  • Innovative approach,
heterosubtypic protection in mice, ferrets, primates Q3-2015 Results in animals Academic labs

N=698

N=373 N=150 N=60 N=49 N=96

slide-17
SLIDE 17

SUMMARY FINANCIAL DATA

Financial Data Highlights

  • Lean structure with 15 employees, current burn ~$250K/month
  • 6.5M outstanding ADS1 (8.7M fully diluted)
  • Clinical studies sponsored by 3rd parties (UNISEC, NIH/NIAID)
  • $4.8M royalty-based liabilities from OCS grants (Office of the Israeli

Chief Scientist grants, off balance sheet)

Balance Sheet Highlights

  • >$22M cash on hand, no debt (~$32M invested to date)
  • €20M EIB non-dilutive funding agreement2 signed June 2017
  • Secondary offering Sept 2017, $10M gross proceeds

BVXV

BVXVW

American Depository Shares ticker:

17

1 1 ADS = 40 ordinary shares 2 European Investment Bank (EIB) €20M support for M-001 Phase 3 trials and commercial production also includes:
  • Zero-percent fixed interest loan for five years after each of the 3 drawdowns
  • Variable remuneration based on royalties of net sales
  • Milestone based drawdowns. Ultimate milestone includes regulatory authorization to launch Phase 3 trial

BVXV

Ordinary Shares ticker: Voluntarily delisting from TASE: Last trading day January 18, 2018 Delisting January 22, 2018

slide-18
SLIDE 18

FLU VACCINES – A LARGE AND GROWING MARKET

Global Flu Vaccine Sales - 2015

$1,435M6 $410M5 $290M8 $652M7

Flu Vaccine Market Seasonal Flu

  • Worldwide: $4B global market in 20151;

expected to grow to $5.3B2 by 2021

  • US: $1.4B in 2012 growing to $2.6B by 20222
  • ~140M doses in just the US2
  • Forecasted CAGR of 5.7%2

Pandemic Flu

  • Swine Flu (A/H1N1) 2009 + first half of 2010

sales: ~$6.4B worldwide by Novartis, GSK and Sanofi (on top of seasonal flu vaccine sales)3 “…part of the national strategy for pandemic influenza, the United States’ plan is to stockpile enough pre-pandemic influenza vaccines to cover 20 million in the critical workforce.”4 “The United States has spent approximately $1 billion in these [H5N1 flu vaccine stockpile] efforts to date.”4

2014: GSK bought Novartis’ vaccine unit except the Flu 2014: CSL bought Novartis’ Flu vaccine unit 2015: Rebrands to Seqirus

Others

2014: Pfizer bought Baxter’s Flu vaccine unit

18

(1) http://www.cnbc.com/2015/10/19/the-16-billion-business-of-flu.html (2) Datamonitor report: DMKC0107117, Publication Date: 18/11/2013 (3) http://www.reports-research.com/news/datamonitor-vaccine-market-overview- 2010.html [Accessed 20 Nov 2016] (4) http://www.who.int/immunization/sage/meetings/2013/november/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf (5) GSK, http://us.gsk.com/en-us/about-us/what-we- do/vaccines/ (6) Sanofi, http://en.sanofi.com/Images/40570_20160209_Results-2015_presentation.pdf, slide 11 [At 31 Dec 2015 exchange rate of 1.08573] (7) CSL/Seqirus, http://annualreport.csl.com.au/year-in-review/seqirus.htm (8) FiercePharma, http://www.fiercepharma.com/pharma/astrazeneca-s-flumist-shunned-by-cdc-group-resulting-80-million-inventory-hit [5,6,7,8 Accessed 25 January 2017] Sanofi 36% Seqirus / CSL (Novartis) 16% GSK 10% AZ 7% Others 31%
slide-19
SLIDE 19

MANAGEMENT

One • For All : The Universal Flu Vaccine

Ron Babecoff

DMV, MEI

Tamar Ben- Yedidia

PhD

Uri Ben-Or

CPA, MBA

Shimon Hassin

PhD

Joshua Phillipson

  • Hon. BSc

Kenny Green

Msc, Mres

Founder, President & CEO CSO CFO COO BD Manager Investor Relations

  • Degree from University of
Liège (ULG)
  • Master in
Entrepreneurship & Innovation (ISEMI, Swinburne)
  • Omrix Biopharmaceuticals
Ltd (Marketing Manager)
  • Dexcel Pharma (Regional
Export Manager)
  • Co-inventor of the
universal flu vaccine
  • Degree from Weizmann
Institute of Science
  • Biotechnology General
Ltd.
  • Degree from College of
Administration
  • Glycominds Ltd. (VP
Finance)
  • Menorah Capital Markets
(Comptroller)
  • Degree from University of
Maryland Biotechnology Institute
  • Kadimastem (CEO)
  • InSight
Biopharmaceuticals (Head
  • f Bioprocessing)
  • Hon. BSc. from University
  • f Toronto
  • Accenture (Business
Management Consultant)
  • BioData Ltd. (Marketing
Manager)
  • Masters in Management
Degree from Cambridge University & Master of Research from University
  • f London
  • IR for leading public
Israeli companies including Elbit Systems and Tower Semiconductor

19

slide-20
SLIDE 20

One • For All : The Universal Flu Vaccine

BOARD OF DIRECTORS

Board Biodar (CEO), Rodar (Founder), Israel Biotech Organization (Chairman, Steering committee)

  • Prof. Avner Rotman, PhD

Chairman of the Board Rosen Partners LLC (Founder), CompreMedx Chairman), Kuala Healthcare (CEO & President), Fusion Telecommunications (Director)

  • Mr. Jack Rosen

Director ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital (Consultant)

  • Dr. George Lowell, MD

Director Omrix Pharmaceuticals Ltd (Marketing Manager), Dexcel Pharma Technologies Ltd. (Formerly Dexxon, Regional Export Manager)) Ron Babecoff, DMV, MEI Founder, President and CEO Credit Suisse First Boston (Investment Banking), Private equity and venture capital funds (Founder)

  • Mr. Isaac Devash, MBA

Director Linkury Technology International Group (CFO), Union Bank, Spectronix, Biomedix incubator, ADO group, Arko holdings, Algomizer (Director)

  • Mrs. Michal Marom Brikman, CPA

Director Mor Langermann (Co-CEO), Medical Compression Systems Ltd (CFO), Excellence Gemel & Pension Funds (External Director)

  • Mr. Ori Mor

Director BioSight Ltd (CEO, Director), SHL Telemedicine (Director), Cellect Biotechnology (Director)

  • Dr. Ruth Ben Yakar, PhD

Director

20

slide-21
SLIDE 21

One • For All : The Universal Flu Vaccine

21

Expiration Date ADS Equivalent Exercise price

NIS ($)

%

ADS Equivalent Shares Outstanding 30 Oct 2017

ADS-Shares 1:40 ratio

75.18% 6,535,490 261,419,599 Ordinary shares Employees Variable $ 7.20 NIS 0.70 ($ 0.18) 3.79% 329,457 13,178,272 Options May 5, 2020 $ 6.25 20.28% 1,762,897 70,515,880 ADS Warrants May 11, 2020 $ 6.25 0.75% 65,425 2,617,000 Warrants issued to underwriters 100.00% 8,693,269 347,730,751 Fully Diluted Shares Outstanding

CAP TABLE

slide-22
SLIDE 22

IP: COMPREHENSIVE AND EXPANDING COVERAGE

Updated: July 2017

One • For All : The Universal Flu Vaccine

22 22

Expiry Status Priority & Assignee Subject Matter International Publication Title Nov 2019 (Aug 2020 for US) Granted: USA, Israel, Australia, Korea, Mexico, New Zealand, Canada, Hong Kong, Belgium, France, Germany, Italy, Netherlands, Spain, Switzerland, UK 11/30/1998 Yeda R&D licensed to BiondVax Vaccine comprising different epitopes
  • f the virus
WO 00/032228 Peptide-Based Vaccine for Influenza Dec 2026 (Jan 2027 for US) Granted: USA, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Luxembourg, Netherlands, Portugal, Sweden, Spain, Switzerland, UK 12/6/2005 Yeda R&D licensed to BiondVax Wide–range vaccines – broad strain and extended protection WO 2007/066334 Improved Influenza Vaccine Aug 2028 (Aug 2031 for US) Granted: USA, Mexico, Russia, Australia, China, Hong Kong, Japan, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Luxembourg, Netherlands, Poland, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, UK, Korea, Israel Filed: Brazil Allowed: Canada Under Examination: India 8/2/2007 BiondVax Vaccines comprising multiple copies of several epitopes – current product WO 2009/016639 Multimeric Multi-Epitope Influenza Vaccines Feb 2031 Granted: USA, Australia Under Examination: Canada BiondVax Use of Multimeric as a primer to conventional vaccines WO 2012/114323 Multimeric Multi-Epitope Polypeptides in improved Seasonal and Pandemic Influenza Vaccines April 2035 Filed: Australia, Canada, Europe, India, China, Hong Kong, Japan, Israel, USA 4/3/2014 BiondVax Production & formulation WO 2015/151103 Vaccine Compositions of Multimeric Multi-epitope Influenza Polypeptides and their Production
slide-23
SLIDE 23

THANK YOU!

CONTACT INFORMATION: JOSHUA PHILLIPSON

j.phillipson@biondvax.com +972-8-930-2529

www.biondvax.com

A game changer for the world healthcare system